Measurement
We believe it is in the interest of clinical laboratories, physicians, and, most of all, our patients that this should occur. In the first place, measurement of apo B and apo A-I have been standardized [3] [4] [5] [6] , whereas measurement of the lipoprotein lipids has not. That alone is a major argument in favor of their assay.
Moreover, apo B appears to be a more accurate clinical measure of atherogenic risk from low-density lipoproteins (LDL) than is total cholesterol or LDL cholesterol. Given the evidence now in hand that marked lowering of LDL substantially reduces the mortality in a large proportion of those with coronary disease [7] , we believe that measurement of apo B should now be available in all clinical laboratories. By contrast, it is not clear that measurement of apo A-I is superior to high-density lipoprotein (HDL) cholesterol as a measure of atherogenic risk. Our comments here, therefore, will center on apo B. The present diagnostic and therapeutic algorithms are built on LDL cholesterol [8, 9] . [26] [27] [28] [29] [30] , and now even clearer evidence is available from a recently completed prospective study [31] . This study-the Quebec Heart Study-demonstrates a threefold increase of risk in type II hypercholesterolemia, in type IV hyperlipoproteinemia with increased apo B, and in normolipidemia with increased apo B. All three phenotypes share a common denominator-an increased number of LDL particles. By contrast, hypertriglyceridemia with a normal apo B number was not associated with any increase in risk.
Not only does measurement of apo B identify those at increased risk, it also points the way to therapy. With the results of the WOSCOPS trial now in hand [32] , plus those of the 4S /7], plus the host of angiographic trials [33] , surely the precedence in therapy must be to lower an increase in LDL particle numbers. The preceding wide and deep array of evidence is the basis for the view that, in hypertriglyceridemic patients with high apo B concentrations, statins-not fibrates-should be the preferred therapeutic route [34] . Similarly, statins are the therapy we prefer for the normolipidemic patient with high apo B who requires therapy. Even with moderate hypercholesterolemia, the degree of abnormality of LDL may be masked if the apo B content is not known. Thus, under virtually any circumstance-the sole exception being marked hypercholesterolemia such as in familial hypercholesterolemia-apo B adds important information.
Simply put: Until the measurement of apo B is available in routine clinical laboratories, doctors cannot make the best choice of therapy for most of their patients.
Cutpoints are essential for clinical decision-making and we present these as suggestions to be considered. But several important issues must be thought through before any specific curpoint values are adopted. For example, it is excellent to have data separated by age and sex because these make it obvious that apo B increases importantly with age and differs with sex [1] . If, however, one chooses age-adjusted cutpoints, one may easily start to think that apo B becomes less dangerous with age-an assumption that seems most unlikely. Therefore, we suggest that the percentile distribution of values for (e.g.) the 50-year-olds be used, after having averaged the results for men and women. In the absence of other risk factors, an apo B value greater than the 75th percentile should be regarded as high risk and a value greater than the 50 percentile as moderate.
We have picked the 50th percentile on the basis of our study [35/ , which showed that <10% of patients with coronary disease had an apo B value less than this. In the presence of other risk factors, a value greater than the 50th percentile should qualify as high risk. In patients at high risk, pharmacological therapy should be considered in addition to diet and weight-loss therapy. With respect to secondary prevention, apo B concentrations should be lowered to at least the 50th percentile.
If data from recent studies such as the 4S [7] point to an incremental benefit with even greater lowering of apo B, then we should amend this recommendation.
We anticipate that target values for apo B will approximate the 30th percentile of the population. Three arguments remain against measuring apo B: Do data from prospective studies support this approach? Would using this approach create unacceptable cost? Would any change in what we measure diminish the credibility of the public campaign against cholesterol?
As to the first, here we disagree with the views of Contois et al. [1] . To be sure, negative studies exist-or rather, studies that have been interpreted as negative, the most influential being that by Stampfer et al. [36] . However, in that study, nonfasting samples were analyzed, the effect of which was to exaggerate the triglyceride and HDL cholesterol deviance from normal. In addition, the question tested was not whether apo B was a better index of risk than total cholesterol or LDL cholesterol but whether apo B was better than the total prognostic information available from the ratio of total to HDL cholesterol plus the clinical risk factors-a tough test indeed! Moreover, at that time, apo B assays were not as reliable as now and certainly were not standardized.
More recent studies have reached different conclusions. For example, Wald et al. [37] found apo B to be the variable most closely associated with risk. More recent data from the Quebec Heart Study [38] confirm and extend these findings. The Quebec Heart Study differs importantly from those previously conducted, which, although prospective, used a case control design. This means that the results for only a small proportion of those in the study were used in the analysis. Usually, such studies include all the cases and a small but variable number of controls. The weakness of this approach is that those chosen to be controls may not adequately reflect the much larger group they are selected from. In the study of Wald et al. [37] , five times as many controls as cases were used-a traditional approach-whereas Stamfer et al.
[ 36] used an equal number of cases and controls-a riskier approach. In any case, in the Quebec Heart Study, the analysis included every participant in the analysis and demonstrated that not only was apo B the single most important determinant of risk but, in fact, was an even better marker of risk than the LDL cholesterol/HDL cholesterol ratio [38] . Also of interest, the EARS study, the largest and most systematic examination of risk factors in the offspruig of fathers with a documented history of early coronary disease [39] , likewise showed apo B to be the best separator of affected subjects from controls of similar age. Thus, apo B better demonstrated risk of coronary disease, whether in the parents or in the progeny.
The second concern is cost. If these latter analytes are not needed at follow-up, the necessity for fasting is avoided, and the number of measurements is reduced. The process of therapy becomes simpler and cheaper.
The third concern is almost always unstated but is perhaps the greatest impediment to change: After so much emphasis on cholesterol as the hallmark for risk assessment, is it possible to change to apo B without confusion and loss of credibility? Fortunately, to state the problem is to overcome it. If change is in the patient's interest, if change leads to more precise diagnosis and treatment, if change makes our practice simpler and in the end less expensive, should we not welcome change rather than resist it? The views we express may challenge conventional practice, but they do not represent a challenge to conventional wisdom. On the contrary, they reemphasize that LDL are key to the pathogenesis of arteriosclerosis and that lowering LDL is key to prevention of its complications. Measuring apo B is simply a better way of measuring LDL than is assaying LDL cholesterol or total cholesterol.
